已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis

埃法维伦兹 病毒载量 杜鲁特格拉维尔 拉米夫定 养生 内科学 医学 逻辑回归 队列 抗逆转录病毒疗法 人类免疫缺陷病毒(HIV) 病毒学 病毒 慢性肝炎
作者
Vanessa Aracele Rodrigues,Maria das Graças Braga Ceccato,Juliana de Oliveira Costa,Celline Cardoso Almeida-Brasil,Micheline Rosa Silveira,Edna Afonso Reis
出处
期刊:Aids Care-psychological and Socio-medical Aspects of Aids/hiv [Taylor & Francis]
卷期号:35 (7): 976-981 被引量:2
标识
DOI:10.1080/09540121.2022.2072802
摘要

Levels of adherence to antiretroviral therapy (ART) can affect the likelihood of viral suppression differentially among ART regimens. In this prospective cohort conducted in Belo Horizonte, Brazil, we included 354 individuals who initiated ART containing tenofovir disoproxil fumarate/lamivudine/efavirenz in fixed-dose combination (TDF/3TC/EFV) or tenofovir disoproxil fumarate/lamivudine associated with dolutegravir (TDF/3TC + DTG). Viral suppression (viral load <50 copies/mL) was evaluated within six months of follow-up at different adherence levels and by therapeutic regimen. Adherence was measured by the Proportion of Days Covered (PDC) and classified into low (≤84%), intermediate (85-89%) or high (≥90%). The association between viral suppression, adherence levels, and other explanatory variables was analyzed using chi-square and multivariable logistic regression. Viral suppression was achieved by 76.0% of individuals and was more frequent among those who achieved higher levels of adherence (high adherence: 79.3%, intermediate: 71.4% and low: 45.2%), those on TDF/3TC + DTG, and those who had viral load ≤100,000 copies/mL at the onset of treatment (p < 0.05). Moreover, individuals on TDF/3TC + DTG had an approximately 90% probability of achieving viral suppression at intermediate adherence levels. These results add new insights on the possibility of lower adherence levels for contemporary antiretroviral regimens currently used as first-line therapy worldwide.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yy发布了新的文献求助10
1秒前
向阳发布了新的文献求助10
3秒前
6秒前
箫扬乘风完成签到,获得积分10
9秒前
SASI完成签到 ,获得积分10
12秒前
明理道之完成签到,获得积分10
12秒前
鲸鱼完成签到,获得积分10
14秒前
柳叶完成签到 ,获得积分10
14秒前
铲屎大王完成签到 ,获得积分10
22秒前
111发布了新的文献求助10
22秒前
破晓心生给破晓心生的求助进行了留言
26秒前
26秒前
27秒前
雾雨星空完成签到 ,获得积分20
29秒前
胖大海完成签到 ,获得积分10
29秒前
十三完成签到 ,获得积分10
30秒前
X_x完成签到 ,获得积分10
31秒前
ZBRTZY发布了新的文献求助30
34秒前
小茵茵完成签到,获得积分10
36秒前
sunzeyu发布了新的文献求助10
36秒前
39秒前
42秒前
42秒前
幸福的小刺猬完成签到 ,获得积分10
43秒前
43秒前
BigTong应助科研通管家采纳,获得10
43秒前
FashionBoy应助科研通管家采纳,获得10
44秒前
ggghh应助科研通管家采纳,获得10
44秒前
共享精神应助科研通管家采纳,获得10
44秒前
大个应助科研通管家采纳,获得10
44秒前
初景应助科研通管家采纳,获得30
44秒前
Hello应助科研通管家采纳,获得10
44秒前
Jeff_Lin应助科研通管家采纳,获得10
44秒前
大个应助科研通管家采纳,获得10
44秒前
Baimei应助科研通管家采纳,获得10
44秒前
小二郎应助科研通管家采纳,获得10
44秒前
Baimei应助科研通管家采纳,获得10
44秒前
CodeCraft应助科研通管家采纳,获得10
44秒前
NexusExplorer应助科研通管家采纳,获得10
44秒前
东方元语应助科研通管家采纳,获得20
44秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Gründe der Seele:Die Wiener Psychatrie im 20.Jahrhundert 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7273986
求助须知:如何正确求助?哪些是违规求助? 8895040
关于积分的说明 18804387
捐赠科研通 6947763
什么是DOI,文献DOI怎么找? 3205550
关于科研通互助平台的介绍 2377131
邀请新用户注册赠送积分活动 2180456